�ݺ�ߣ

Editor's Notes

• #1: Your excellencies, esteemed delegates and colleagues, I am privileged to present to you, on behalf of the WHO Secretariat of the Regional Committee, a brief overview of the technical paper proposing accelerating of the regional response to antimicrobial resistance through collaborative action.
• #2: There has been significant progress since the Global Action Plan on AMR was adopted at the 68th WHA in May 2015. This roadmap shows significant global achievements across stakeholders and domains of work, almost for every year since 2015. Highlights include the setting up of a global antimicrobial resistance and surveillance system in that year itself that countries in the region use, a UN HLM in 2016, the setting up of the IACG in 2017 and the partnership between WHO, FAO and WOAH in 2018 that became the quadripartite in 2022 with the joining of UNEP. Global outcomes that have guided progress include the IACG report of 2019, the Muscat Manifesto on 2022 and WHOs people-centred approach published in 2023 which underpins the recommendations in this technical paper. In 2024, we stand at an inflection point in the global fight against AMR!
• #3: As of March 2024, all countries have developed their first AMR national action plan; and some have progressed to revisions and updates. However, only three report allocation of national budget for the implementation of their plans. All countries have enrolled in the WHO global AMR surveillance system. As of 2023, 16 countries report AMR data and 10 report consumption data. The COVID-19 pandemic catalysed the strengthening of IPC programmes and systems and 17 countries in the region have set up dedicated IPC units or programmes. There are several clinical, laboratory and epidemiological studies on resistance patterns ongoing with at least 12 implementation research projects in the region. Supply chain interruptions remain a challenge to the access to health services for the prevention, diagnosis and management of infectious diseases. Although countries manufacture antibiotics, they lack capacity for the production of active pharmaceutical ingredients and failures in global supply chains result in shortages of specific antibiotics. Several important interventions are in place despite the challenges and the context!
• #4: �ݺ�ߣ 4a Among WHO regions, and globally, the Eastern Mediterranean Region has the highest and most rapidly rising levels of antibiotic consumption. This graph shows that the region consumes antibiotics at a higher rate per capita than the rest of the world. �ݺ�ߣ 4b Within the region, we notice that this trend is increasing across countries, although there is a welcome recent decline in the high-income group of countries. The lower consumption per capita in the FCV group of countries could be masking issues around access to essential antibiotics which is also a serious challenge. It must be noted that although almost all countries restrict the use of antibiotics for growth promotion, antibiotic consumption in animal health and food production is high. Antibiotics are frequently used inappropriately, mostly as a substitute for good hygiene and biosecurity measures.
• #5: A recently published study estimates that in 2021, antimicrobial resistance is estimated to have killed 1.14 million people globally. The number of deaths attributable to AMR outpaces the annual global burden of HIV or malaria that are estimated to kill 630 000 and 600 000 people, respectively. Global Antimicrobial Resistance and Use Surveillance System (GLASS) AMR data indicates that the Region has a high prevalence of bloodstream infections due to both methicillin-resistant Staphylococcus aureus (MRSA) and Escherichia coli resistant to third-generation cephalosporin (ESBL-E. coli) among reported isolates (SDG target 3.d.2). GLASS data for the Region in 2021 indicate that the mean proportion of all bloodstream infections due to ESBL-E.coli reached 66%, while the mean proportion of all bloodstream infections due to MRSA reached 53% Implementation of AMS programmes by hospital and countries is varied and inappropriate use of antibiotics is high! In 2023, only five out of 10 countries reporting data achieved the targeted 60% share for Access antibiotics in the most recent year for which data were available, only 61% of prescriptions documented a reason for antibiotic use, and only 21% of antibiotic use was based on culture results. ________________________________________________________________________ researchers from the Global Research on ARM (GRAM), a partnership between the Institute for Health Metrics and Evaluation (IHME) and Oxford University, published a new forecast for the global AMR burden. From 2025 to 2050, AMR will cause 39 million deaths if we do not scale up interventions and investment now - this is three deaths every minute.
• #6: SEVEN countries reported carbapenem resistant bacteria as the most fatal AMR in 2021 compared to ZERO countries in 2019
• #7: Our strategic regional priorities are built on the global strategic priorities and PCA you endorsed in WHA in May. Considerating the complex challenges in our region , the regional SP to address AMR are incorporated with regional priories for building resilient health system that you adopted 2 years ago we presenting 5 key strategic properties with specific measurable interventions
• #8: Our strategic regional priorities are built on the global strategic priorities and PCA you endorsed in WHA in May. Considerating the complex challenges in our region , the regional SP to address AMR are incorporated with regional priories for building resilient health system that you adopted 2 years ago we presenting 5 key strategic properties with specific measurable interventions
• #9: Relevant to almost all the program , many essential public health such AmR will not be in silo h as
• #10: The only program of health in UNGA ,